Clinical Trials Logo

Rheumatoid Arthritis clinical trials

View clinical trials related to Rheumatoid Arthritis.

Filter by:

NCT ID: NCT04749160 Completed - Clinical trials for Rheumatoid Arthritis

Smart Marker Annunciating Response to Rheumatologic Treatments SMART²T

SMART²T
Start date: June 4, 2021
Phase:
Study type: Observational

European recommendations indicate to start a conventional synthetic disease modifying antirheumatic drug (csDMARD) as soon as possible to reach the remission in early RA or low disease activity in established RA. If the target is not achieved with the first csDMARD and in presence of poor prognostic, addition of a biologic (b)DMARD or a targeted synthetic (ts)DMARD should be considered . Nevertheless, as many as one-third of patients have persistent disease activity and insufficient (inadequate) response to a first b/tsDMARD according to international recommendations. This relatively long time (3 to 6 months) between treatment initiation and determination of individual clinical response represents: - a risk for the patient who could be usually exposed to potential side effects, - a loss of chance for the patient who will not receive an adequate treatment during the most favorable period and thus may develop irreversible lesions - a cost for the healthcare system, especially in terms of expensive drug reimbursements, notwithstanding the increasing use of biosimilars. Despite 20 years of research, no biomarker or no way are available in the daily practice to predict disease activity and the non-response to a b/tDMARD [11]. Thus exploration of a new approach is totally in purpose. The aim of this project is to benefit from the declarative PRO (Patient Reported Outcomes), the physical activity and sleep quality to predict the individual clinical response to the b/tsDMARDs

NCT ID: NCT04748809 Recruiting - Clinical trials for Rheumatoid Arthritis

Effect of Anti-inflammatory Diet in Rheumatoid Arthritis

Start date: November 1, 2020
Phase: N/A
Study type: Interventional

In a previous exploratory study, the investigators observed an effect on disease activity outcomes of anti-inflammatory diet. The investigators also observed change in microbiome and circulating metabolites. The current study will determine whether or not the addition of anti-inflammatory diet improves the clinical outcomes in participants with rheumatoid arthritis, and the role of microbiome and circulating metabolites.

NCT ID: NCT04740814 Completed - Clinical trials for Rheumatoid Arthritis

A Study to Assess the Pharmacokinetics of Certolizumab Pegol in Adults With Active Rheumatoid Arthritis

Start date: February 11, 2021
Phase: Phase 1
Study type: Interventional

The purpose of the study is to evaluate the pharmacokinetics and safety of certolizumab pegol in adults with active rheumatoid arthritis.

NCT ID: NCT04734496 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Evaluation of the Mechanisms of Sarcopenia in Chronic Inflammatory Disease: Protocol for a Prospective Cohort Study

Start date: January 1, 2019
Phase:
Study type: Observational

Prospective, observational study to assess sarcopenia across three chronic inflammatory diseases: chronic liver disease, Inflammatory Bowel Disease, Rheumatoid Arthritis both before and after therapeutic intervention (standard of care treatment i.e. nutrition/exercise; biologic for IBD etc).

NCT ID: NCT04709354 Completed - Clinical trials for Rheumatoid Arthritis

Clinical and Dermoscopic Comparison of Rheumatoid Arthritis, Ankylosing Spondylitis and Psoriasis Patients' Nails

Start date: January 1, 2021
Phase:
Study type: Observational

This study evaluates the fingernail findings of the rheumatoid arthritis, spondylopathy and psoriatic arthritis patient groups with the fingernails of psoriasis patients clinically and dermatoscopically and investigates the benefit of dermoscopy in the differentiation of these patients.

NCT ID: NCT04704492 Completed - Clinical trials for Rheumatoid Arthritis

A Study of the Pharmacokinetics and Safety of SM03 in Patients With Rheumatoid Arthritis

Start date: August 14, 2012
Phase: Phase 1
Study type: Interventional

This was an open phase I trial to evaluate the pharmacokinetic, pharmacodynamic, safety and clinical activity profiles of anti-CD22 monoclonal antibody SM03 in patients with active RA.

NCT ID: NCT04696718 Recruiting - Clinical trials for Rheumatoid Arthritis

Determination of the Biological Activity of Serum From Patients

nutricell3
Start date: December 20, 2018
Phase: N/A
Study type: Interventional

The main objective of the study is to determine the influence of patient sera before and after probiotic intervention on the behavior of bone cells (osteoblasts and osteoclasts). The secondary objectives are to assess the activity of bone cells and the course of rheumatoid arthritis before and after the consomption of probiotics.

NCT ID: NCT04692493 Recruiting - Clinical trials for Rheumatoid Arthritis

RA-PRO PRAGMATIC TRIAL

RA-PROPR
Start date: September 22, 2021
Phase: Phase 3
Study type: Interventional

The 2021 ACR RA treatment guideline, based on widely acknowledged low to moderate quality evidence, recommends switching to a non-tumor necrosis factor (TNFi) biologic (choose among existing medications, currently, rituximab, abatacept, tocilizumab, or sarilumab) or a targeted synthetic DMARD arm (tsDMARD; choose among existing medications, currently, tofacitinib, baricitinib, upadacitinib) in patients with active RA despite the use of a TNFi-biologic. In practice, most patients receive another TNFi-biologic, i.e., a second TNFi-biologic first. This is not based on solid evidence, but on arbitrary algorithms often proposed by health insurance plans, and/or physician experience and habit (TNFis launched 22 yrs ago vs. the first tsDMARD 8 years ago vs. first non-TNF-biologic launched 17 years ago). This study will fill a critical knowledge gap by generating CER data for important PROs between these treatment options, switching to a non-TNFi biologic or a tsDMARD in patients with active RA despite the use of a TNFi-biologic.

NCT ID: NCT04691505 Completed - Clinical trials for Rheumatoid Arthritis

Data Analysis for Drug Repurposing for Effective Alzheimer's Medicines (DREAM) - Methotrexate vs Hydroxychloroquine

Start date: December 23, 2020
Phase:
Study type: Observational

This study aims to evaluate the comparative risk of dementia/Alzheimer's disease onset between patients treated with medications that target specific metabolic pathways and patients treated with alternative medications for the same indication.

NCT ID: NCT04684693 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Effect of Laser Puncture on Rheumatoid Arthritis Patients

Start date: December 25, 2020
Phase: N/A
Study type: Interventional

Studying the effect of laser puncture on rheumatoid arthritis patients